CA3080128A1 - Composes de selenogalactoside pour le traitement de troubles de la resistance systemique a l'insuline et leur utilisation - Google Patents

Composes de selenogalactoside pour le traitement de troubles de la resistance systemique a l'insuline et leur utilisation Download PDF

Info

Publication number
CA3080128A1
CA3080128A1 CA3080128A CA3080128A CA3080128A1 CA 3080128 A1 CA3080128 A1 CA 3080128A1 CA 3080128 A CA3080128 A CA 3080128A CA 3080128 A CA3080128 A CA 3080128A CA 3080128 A1 CA3080128 A1 CA 3080128A1
Authority
CA
Canada
Prior art keywords
group
substituted
heteroaryl
naphthyl
group substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3080128A
Other languages
English (en)
Inventor
Peter G. Traber
Eliezer Zomer
Deirdre SLATE
Joseph M. Johnson
Ryan George
Sharon Shechter
Raphael NIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galectin Sciences LLC
Original Assignee
Galectin Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences LLC filed Critical Galectin Sciences LLC
Publication of CA3080128A1 publication Critical patent/CA3080128A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Selon des aspects, la présente invention concerne de nouveaux composés synthétiques ayant une affinité de liaison avec des protéines de galectine pour le traitement de troubles de la résistance systémique à l'insuline.
CA3080128A 2017-10-31 2018-05-11 Composes de selenogalactoside pour le traitement de troubles de la resistance systemique a l'insuline et leur utilisation Pending CA3080128A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579343P 2017-10-31 2017-10-31
US62/579,343 2017-10-31
PCT/US2018/032321 WO2019089080A1 (fr) 2017-10-31 2018-05-11 Composés de sélénogalactoside pour le traitement de troubles de la résistance systémique à l'insuline et leur utilisation

Publications (1)

Publication Number Publication Date
CA3080128A1 true CA3080128A1 (fr) 2019-05-09

Family

ID=66332241

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3080128A Pending CA3080128A1 (fr) 2017-10-31 2018-05-11 Composes de selenogalactoside pour le traitement de troubles de la resistance systemique a l'insuline et leur utilisation

Country Status (8)

Country Link
EP (1) EP3707149A1 (fr)
JP (1) JP2021501180A (fr)
KR (1) KR20200081443A (fr)
CN (1) CN111527097A (fr)
AU (1) AU2018361991A1 (fr)
CA (1) CA3080128A1 (fr)
IL (1) IL274162A (fr)
WO (1) WO2019089080A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
EP4010348B1 (fr) * 2019-08-09 2023-12-20 Idorsia Pharmaceuticals Ltd Dérivés de (2-acétamidyle)thio-bêta-d-galactopyranoside
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
JP7604457B2 (ja) 2019-08-15 2024-12-23 イドルシア・ファーマシューティカルズ・リミテッド ２－ヒドロキシシクロアルカン－１－カルバモイル誘導体
CA3148365A1 (fr) * 2019-08-29 2021-03-04 Martin Bolli Derives d'alpha-d-galactopyranoside
EP4684799A2 (fr) * 2019-12-06 2026-01-28 TrueBinding, Inc. Anticorps qui désexcitationent l'interaction entre gal3 et le récepteur de l'insuline ou les intégrines et leurs procédés d'utilisation
WO2021242776A2 (fr) 2020-05-26 2021-12-02 Truebinding, Inc. Méthodes de traitement de maladies inflammatoires par blocage de la galectine-3
ES3014851T3 (en) 2020-10-06 2025-04-25 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
KR20230104190A (ko) 2020-11-02 2023-07-07 이도르시아 파마슈티컬스 리미티드 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物
KR20230145111A (ko) 2021-02-09 2023-10-17 이도르시아 파마슈티컬스 리미티드 히드록시헤테로시클로알칸-카르바모일 유도체
PL4301748T3 (pl) 2021-03-03 2025-09-08 Idorsia Pharmaceuticals Ltd Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu
WO2025084276A1 (fr) * 2023-10-16 2025-04-24 Ｃｙｎ－Ｋバイオ株式会社 Traitement de l'obésité
JP1779660S (fr) 2024-05-09 2024-09-11
JP1779661S (fr) 2024-05-09 2024-09-11

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6904906B2 (ja) * 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
CN105318222B (zh) * 2015-11-13 2018-07-27 南通亚泰蜡业工艺品有限公司 喷泉电子蜡烛
JP7086008B2 (ja) * 2016-03-04 2022-06-17 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー ガレクチンに関連する疾患を予防および処置するためのセレノガラクトシド化合物およびその使用

Also Published As

Publication number Publication date
EP3707149A1 (fr) 2020-09-16
JP2021501180A (ja) 2021-01-14
WO2019089080A9 (fr) 2020-07-23
CN111527097A (zh) 2020-08-11
AU2018361991A1 (en) 2020-05-14
WO2019089080A1 (fr) 2019-05-09
KR20200081443A (ko) 2020-07-07
IL274162A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
CA3080128A1 (fr) Composes de selenogalactoside pour le traitement de troubles de la resistance systemique a l'insuline et leur utilisation
US20200061095A1 (en) Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof
US20230132265A1 (en) Compounds for the prevention and treatment of diseases and the use thereof
US20230127345A1 (en) Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
KR102692840B1 (ko) 의학적 장애의 예방 및 치료를 위한 화합물 및 이의 용도
BR112018067693B1 (pt) Selenogalactosídeos, seus usos, e composição

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250407